Veracyte Inc. (VCYT)

Name: Veracyte Inc. (VCYT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Veracyte Inc. (VCYT)

Stock Card

$43.01

$-0.34 (-0.77%)

As on 31-Aug-2026 14:36EDT

Market cap

$3,484 Mln

Revenue (TTM)

$562 Mln

P/E Ratio

32.3

P/B Ratio

2.6

Div. Yield

0 %

Veracyte (VCYT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 41.60 High: 43.11

52 Week Range

Low: 29.38 High: 60.91

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

23.3
Debt to Equity

0
Book Value

$--
EPS

$1.4
Face value

--
Shares outstanding

80,390,731

10 Years Aggregate

CFO

$-112.82 Mln

EBITDA

$-225.21 Mln

Net Profit

$-387.29 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Veracyte (VCYT)	2.1	-28.1	-7.2	41.7	17.6	-2.5	22.7
BSE Sensex	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Veracyte (VCYT)	6.3	43.5	15.9	-42.4	-15.8	75.3	121.9
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Veracyte (VCYT)	43.0	3,484.1	561.9	114.5	19.4	8.5	32.3	2.6
Arrowhead Pharmaceuticals (ARWR)	81.0	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	263.3	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	70.0	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.3	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	106.1	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	354.8	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	530.1	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	589.3	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	342.5	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Veracyte (VCYT)

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis;... Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Read more

CEO & Director

Mr. Marc A. Stapley
CEO & Director

Mr. Marc A. Stapley
Headquarters

South San Francisco, CA
Website

https://www.veracyte.com

FAQs for Veracyte (VCYT)

What is the current share price of Veracyte Inc (VCYT) Today?

The share price of Veracyte Inc (VCYT) is $43.01 (NASDAQ) as of 31-Aug-2026 14:36 EDT. Veracyte Inc (VCYT) has given a return of 17.56% in the last 3 years.

What is the current PB & PE ratio of Veracyte Inc (VCYT)?

The P/E ratio of Veracyte Inc (VCYT) is 32.34 times as on 28-Aug-2026.
The P/B ratio of Veracyte Inc (VCYT) is 2.62 times as on 28-Aug-2026, a 49 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.